Metabolic Surgery for Atrial Fibrillation Elimination
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT07027969
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT07027969
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07027969. Randomized; no masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metabolic Surgery for Atrial Fibrillation Elimination
- Acronym
- METSAFE
- Condition
- Atrial Fibrillation
- Condition
- Obesity and Obesity-related Medical Conditions
- Intervention (Procedure)
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
- Intervention (Drug)
- Anti-Obesity Medication (AOM) treatment
- Lead sponsor
- Ali Aminian
- Collaborator
- Ethicon, Inc.
- Collaborator
- iRhythm Technologies, Inc.
Record details
- Record id
cardio:ct-nct07027969- Content hash
166635191a27e9e1422b893d156b14b8c5425127b80adb9f75a8a3bb7eb22edc